Author byline as per print journal: Professor Brian Godman1,2,3, BSc, PhD; Amanj Kurdi1,4, PhD; Holly McCabe5, MSc; Sean MacBride-Stewart6, MSc; Axel Leporowski5, MD; Simon Hurding7, MD; Professor Marion Bennie1, MSc; Professor Alec Morton5, PhD
Introduction: There has been a considerable increase in the use of proton pump inhibitors (PPIs) in recent years due to their effectiveness versus H2 antagonists. This includes reducing GI bleeds in patients at risk. However, there are concerns with their long-term use and potential costs. Costs can be reduced with increased prescribing of low-cost generic PPIs.
Submitted: 2 September 2018; Revised: 29 October 2018; Accepted: 30 October 2018; Published online first: 12 November 2018
With ageing populations, the increasing prevalence of chronic diseases, and polypharmacy, the proton pump inhibitors (PPIs) have become one of the most prescribed medicines among Western countries [1–4]. We are also seeing increased use of PPIs among Central and Eastern European (CEE) countries . However, this is not universal as there are prescribing restrictions and co-payments for PPIs in some CEE countries, such as Lithuania and Serbia, which appreciably limited their use versus Western European countries [2, 5].
Upper gastrointestinal (GI) symptoms have a substantial impact on patients as well as healthcare utilization across countries. For instance, up to 10% of general practitioner (GP) consultations in the UK are for dyspepsia . The prescribing of PPIs has increased in recent years with studies showing them to be more effective than H2 antagonists in both preventing and healing ulcers as well as reducing GI bleeds [7–13]. This is important if patients are on long-term treatment such as nonsteroidal anti-inflammatory drugs (NSAIDs) for pain or a combination of antiplatelet and anticoagulant treatment [14–16]. In the early 2000s, there were also concerns at the extent of GI bleeding causing admissions to hospitals in the UK with encouragement of greater use of PPIs [17, 18], although they still occur leading to over 9,000 deaths annually in the UK . As a result of these various factors, omeprazole was the most frequently prescribed medicine in Scotland in 2014 and 2015 . The high use of PPIs has also been seen in other countries and sectors [3, 20–25], with their usage enhanced in some countries by non-guideline prescribing .
However, there are concerns that long-term use of PPIs can have patient safety issues [1, 26]. Safety concerns include increasing the rate of community-acquired pneumonia, increasing the number of fragility fractures, as well as increasing the number of clostridium difficile infections (CDI) possibly due to changes in the gut microbiomes. In addition, increasing the number of norovirus infections as well as increasing the extent of chronic kidney disease and hypomagnesemia [19, 20, 27–37]. These concerns have resulted in guidance from the Greater Glasgow and Clyde Health Board in Scotland and others to suggest that patients on PPIs long term, and at risk of osteoporosis, should have an adequate intake of calcium and vitamin D [19, 38]. Patients on PPIs long term should also have their serum magnesium levels regularly checked especially if they are taking digoxin or other medicines known to cause hypomagnesaemia . PPIs should also be stopped where possible in those patients with suspected or actual CDIs [19, 39, 40]. Such considerations though have to be balanced against the undoubted effectiveness of PPIs in preventing and healing ulcers, controlling symptoms of dyspepsia and heartburn, as well as reducing hospital admissions and deaths due to GI bleeds.
Concerns with the possible adverse effects of long-term PPIs resulted in guidance to GPs in Scotland from mid to late 2000s onwards to prescribe the lowest possible dose, and also generally to review patients on PPIs long term at least annually [27, 41–43]. This builds on earlier advice from National Health Service (NHS) Scotland to enhance the prescribing of maintenance doses of PPIs rather than healing doses whenever possible as a measure of the quality of prescribing . The proportion of high strength versus low strength PPIs has subsequently been monitored and benchmarked between the different Regional Health Boards in Scotland as an indicator of the quality of GP prescribing, with GPs encouraged, as mentioned, to regularly review patients prescribed high strength PPIs [14, 16, 27, 45, 46]. Quality Indicators (process) discouraging the prescribing of high strength PPIs were also included in the Scottish National Therapeutic Indicators (NTI) list in 2012; however, they were dropped from 2013 [27, 45] onwards to just concentrate on overall PPI utilization. This change was because the Scottish Government advisers, chaired by two of the co-authors, believed that the majority of potential reductions in the strength of PPIs prescribed by GPs had already taken place by 2013, and there was limited additional benefit to carry on with this NTI compared with other more important NTIs. If they wish to prescribe higher strength omeprazole, GPs were encouraged to prescribe 2 x 20 mg capsules omeprazole rather than one 40 mg capsule as this could be up to 60% less expensive.
Increased prescribing of PPIs is a concern where there is limited use of low-cost generic PPIs compared with appreciably more expensive patented PPIs as this will drive up ambulatory care expenditure without improving patient outcomes with all PPIs seen as essentially similar at comparable therapeutic doses . Expenditure on PPIs in countries where there have been limited initiatives to increase the prescribing of multiple sourced (generic) PPIs versus on patent PPIs has been up to ten times greater when adjusted for population size compared with European countries who actively promoted the preferential prescribing of generic PPIs through multiple initiatives and measures .
Such differences in expenditure are a major concern where resources are limited as this will reduce available resources to be spent on other priority disease area. To address this, the Scottish Government, coupled with the Regional Health Boards in Scotland, introduced a range of measures and initiatives in recent years to encourage the prescribing of multiple-sourced products where this does not compromise care [48, 49]. These measures were in addition to existing initiatives in Scotland to encourage the prescribing of lower dose PPIs as well as encourage International Nonproprietary Name (INN) prescribing. Initiatives to enhance INN prescribing in Scotland included education in medical schools, IT support systems and prescribing targets [49–51], with the prices of generic PPIs as low as 9% of pre-patent loss originator prices . Such activities are necessary in the UK to fully realize the savings from the availability of generics as community pharmacists are currently banned from substituting an originator medicine with a generic if the physician prescribes the originator . This is unlike for instance the situation in Sweden where there is compulsory generic substitution or France where pharmacists have agreed targets for substitution [53, 54]. There is also no obligation for the originator company in the UK to lower its prices to be reimbursed once generics become available as there is no internal reference pricing system. This is unlike a number of other European countries . Low prices for generics in the UK followed the introduction of the ‘M’ and ‘W’ scheme (Manufacturer and Wholesaler) in April 2005, which enhanced transparency in the prices of generics . Prior to this, prices of generics were less transparent in the UK as witnessed by generic manufacturers offering discounts of up to 80% or more on their list prices to increase their sales volumes . There are also no concerns with INN prescribing among GPs in the UK apart from a limited number of situations, unlike the situation in other European countries [52, 56–59].
Initiatives to encourage the prescribing of multiple-sourced (generic) PPIs first line in Scotland versus patented PPIs included education, prescribing targets and financial incentives [42, 48, 49]. Generic PPIs have been endorsed over originators and patented PPIs in view of the considerable cost differences and limited differences in effectiveness between them at equivalent doses, with generic omeprazole and generic lansoprazole typically endorsed over other generic PPIs in Scotland as they had lower prices [19, 27, 41, 42, 49, 60, 61]. These combined measures have resulted in considerable savings in the past in Scotland . This is similar to the multiple activities that have been instigated nationally and regionally in Scotland to enhance prescribing efficiency for lipid lowering medicines with similar results .
There has also been Scottish Guidelines (SIGN – Scottish Intercollegiate Guidelines Network) issued in 2003 educating physicians on the management of dyspepsia including the prudent use of PPIs .
In this paper, we will seek to further analyse the influence of these multiple activities instigated by the Scottish Government combined with the Health Boards in Scotland to improve efficient prescribing of PPIs in ambulatory care as well as the prescribing of lower strength PPIs. We will also evaluate the influence of changing PPI prices on the prescribing mix. This builds on our previous publications regarding policies to influence the prescribing of multiple-sourced PPIs in Scotland [48, 49]. We have concentrated on ambulatory care as there is limited prescribing of PPIs among hospital inpatients versus ambulatory care in Scotland . The findings will be used to provide guidance to countries struggling to provide comprehensive health care in the face of growing resource pressures driven by ageing populations with more complex diseases.
To assess the utilization and prescribing patterns of PPIs in ambulatory care in Scotland, we analysed the prescription costs analysis (PCA) database . This database is compiled by the Information Services Division (ISD) of NHS Scotland from 2001 to 2017 . This is an open source data set collecting data on the utilization and expenditure of medicines dispensed in community pharmacies in Scotland. It is a robust dataset that is regularly audited and covers the whole of Scotland rather than a selection of community pharmacies. NHS Scotland is a universal healthcare system serving the entire Scottish population [49, 62], with currently no co-payment for medicines in Scotland.
Between 2001 and 2017, the Scottish NHS made five PPIs available to be prescribed. These included omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole. Information extracted from the PCA between 2001 and 2017 included: the generic name, commercial name(s), formulation(s), drug strength(s), number of dispensed units, cost per unit and total gross expenditure. All costs are depicted in Great Britain pounds (GBPs) and depict the gross ingredient costs (GIC) and cost per item for the medicines dispensed. No adjustment for inflation for the prices was made. This is in line with previous studies due to the rapid reduction in prices in the UK once originators such as the PPIs became available as generics [47–49].
Whilst NHS Scotland routinely uses defined daily doses (DDDs) as well as DIDs (DDDs/1,000 inhabitants/day) when discussing and presenting utilization data [16, 27], which is in line with international guidance [27, 45, 64], we typically used items dispensed in community pharmacies in this analysis, although some analyses were undertaken with DDDs. This is because we wanted to track actual prescriptions, especially with physicians being encouraged to prescribe lower strength PPIs. In the case of patients with chronic diseases, such as GERD or dyspepsia, a prescription is usually for 28 or 56 days. However, there has been a tendency in recent years for physicians to increase the length of a prescription to help with their growing workloads . However, cognizant of the need to regularly review the strength of PPIs prescribed for patients on long-term use . We recognize this may influence the analysis of prescribing volumes when compared with DDDs, as well as make comparisons across countries difficult. However, our primary aim was an evaluation of prescribing practices in Scotland.
For each PPI and year, total costs, the total number of dispensed and the expenditure they represent to NHS Scotland were calculated with the totals based on summation of individual items dispensed. In addition, DDDs were also used when researching the influence of different initiatives to encourage the prescribing of lower strength PPIs. The DDDs were calculated based on the number of packs dispensed and their strength . A sub-analysis of the extent of prescribing of generic versus originator PPIs was also undertaken again based on items dispensed. This information was plotted over time in years. The date at which each PPI became available as a generic in Scotland was also obtained from an internal NHS database. The ongoing activities within the Health Boards to improve the quality and efficiency of PPI prescribing have been collated using the 4E methodology, building on previous findings: Education, Engineering, Economics, and Enforcement [48, 49, 65]. Education refers to initiatives such as guidelines and academic detailing; engineering refers to organizational or managerial interventions such as prescribing indicators; economics refers to financial incentives for the prescriber; and enforcement refers to specific regulations from health authorities such as prescribing restrictions or compulsory generic substitution [48, 54, 65, 66]. However, enforcement is very rare in Scotland unlike some other European countries including Austria, Finland, Norway and Sweden [54, 66–69].
No sophisticated analysis, such as time-series analyses was undertaken due to the multiple measures and interventions instigated between 2001 and 2017, and the associated problems with conducting such analyses in these circumstances .
Of the five PPIs included in this study, none were generically available in 2001. By the end of 2012, all five PPIs were available as generics with different formulations and strengths, see Table 1.
A variety of measures were undertaken between 2000 and 2017 to enhance the quality and efficiency of PPI prescribing, see Table 2.
Total PPI utilization increased 3.06-fold between 2001 and 2017, rising from 1.8 million items dispensed in 2001 to 5.5 million items in 2017. The increase in utilization has been driven predominantly by increased utilization of omeprazole and lansoprazole with limited utilization of the other PPIs, see Figure 1.
Concurrent with this, total PPI expenditure fell by 66.7% between 2001 and 2017 from GBP 56.49 million in 2001 to GBP 18.83 million in 2017, see Figure 2.
As seen in Figure 2, expenditure peaked in 2006 before falling rapidly with the availability of both generic omeprazole (2002) and generic lansoprazole (2005) at falling prices, see Figure 3, combined with high rates of INN prescribing in Scotland even when only originators are available. Table 3 contains details of the percentage reduction in cost/items dispensed for the different PPIs in 2017 versus their prices just before patent loss, see Table 1.
INN prescribing in terms of items dispensed varied between 96.7% and 99.1% for omeprazole in recent years versus 87.3% to 100% for pantoprazole, 92.6% to 99% for lansoprazole, 63.5% to 98% for esomeprazole and 42.6% to 96% for rabeprazole. As a result, the cost/item dispensed for the various PPIs appreciably reduced following the launch of generics, see Table 3.
There appears to be a greater reduction in the prescribing of higher strength omeprazole in recent years versus lansoprazole as the two most prescribed PPIs, see Figures 1, 4, 5, with the dispensing of omeprazole further analysed in DDDs.
We believe the appreciably increased prescribing of PPIs over the years, see Figure 1, has been influenced by the 1) high prevalence of dyspepsia in the UK; 2) extent of admissions to UK hospitals due to GI bleeding; 3) increasing elderly patients increasing the extent of polypharmacy and the need for anticoagulation; 4) studies demonstrating the effectiveness of PPIs versus H2 antagonists in preventing as well as healing ulcers [6, 9, 10, 12, 17, 18, 73–75]. However, we cannot say with certainty without further qualitative research.
Similar to the findings with lipid lowering agents , the loss of a patent appears to appreciably influence subsequent prescribing patterns not only for omeprazole following generic availability in 2002, see Table 1, but also for the other PPIs, see Figure 1. The use of lansoprazole stabilized following the availability of generic omeprazole and then rose following the availability of generic lansoprazole (2006/2007 onwards, see Figure 1). This was helped by the endorsement of generic lansoprazole in Regional Health Board Formularies, see Table 2. The utilization of the other PPIs remained low over the years, enhanced by recommendations not to prescribe, see Table 2, Figure 1. Such activities followed appreciable price differences for omeprazole and lansoprazole versus for instance esomeprazole until recent years, see Figure 3 and Table 3. These price differences are hidden from patients as there is currently no co-payment in Scotland; however, prices do have an indirect effect as appreciable price differences between different medicines in a class can result in extensive educational and other activities by the Scottish Government and the Regional Health Boards to influence subsequent prescribing without compromising care, see Table 2. As a result of the various initiatives, the utilization of omeprazole rose 3.66 times between 2001 and 2017, greater than the overall increase in PPI utilization (3.06 times). During this time, expenditure on PPIs fell by 66.7% to just GBP 18.83 million in 2017, aided by multiple initiatives, see Table 2, combined with an appreciable reduction in prices following generic availability, see Table 3.
Overall, the multiple demand-side measures, see Table 2, appear to have successfully moderated or even reduced the prescribing of higher cost PPIs that are perceived to have no additional benefits, see Figures 1 and 2. The multiple measures have also resulted in high INN prescribing rates for the PPIs. High INN prescribing in Scotland is also seen in other disease areas including anticoagulants, anti-depressants, statins for hypercholesterolaemia, antihypertensives and atypical antipsychotics for schizophrenia [48, 62, 76–78]. As a result, providing exemplars to other European countries where there are concerns with generics [58, 59], as well as to other European countries with currently limited demand-side measures resulting in the continued prescribing of higher priced patented medicines with limited additional benefits [47, 48, 79]. This again shows how generic and patented medicines do interact with each other, and affect the way they are prescribed in Scotland, building on the recent findings with the lipid lowering therapies . Again, multiple demand-side measures, see Table 2, appeared necessary to effect changes in prescribing habits, similar to other studies [25, 62, 80–82].
As older PPIs lose their patent and become cheaper, moving away from patented formulations in favour of generic PPIs with similar efficacy and safety profiles can be a reality. This can lead to substantial additional savings within the NHS system despite appreciably increasing volumes, see Figures 1 and 2, although further savings can still be achieved . These savings can be used to fund the increased use of new valued but higher priced medicines as well as funding the increasing use of medicines in Scotland due to ageing populations within current budgets.
There has been some change in the prescribing of lower strength PPIs in recent years following the instigation of quality indicators and other initiatives to improve the quality of PPI prescribing, see Table 2, Figures 4 and 5. However, it is difficult to make any definite statements since GPs in Scotland have typically prescribed two 20 mg tablets as opposed to one 40 mg tablet of omeprazole as this was cheaper. Having said this, the prescribing of 40 mg omeprazole appears to have appreciably fallen in recent years whilst the prescribing of 20 mgs has continued to rise causing the DDDs to continue to rise, see Figure 5. This would suggest some improvement in the quality of prescribing if patients can be adequately managed on 20 mg of omeprazole and 15 mg lansoprazole, which is the case for prophylaxis in patients on NSAIDs, anticoagulants or antiplatelet medicines. This is expected to decrease complications from long-term use of PPIs based on available evidence [19, 27, 38, 39, 41].
We are aware of a number of limitations with this study. The major ones are the fact that we cannot link prescribing of PPIs to any diagnoses with this dataset. In addition, there can be differences between prescribing and dispensing data. We also could not measure adherence rates, which can be a concern among patients on PPIs . In addition, we could not measure any improvements in long-term outcomes from reduced prescribing of high-dose PPIs with the administrative data sets we used. This would need access to patient level data and linked datasets. We are also aware we used GIC costs which includes a small discount before pharmacists are paid. Lastly, as mentioned, we principally used items dispensed rather than DDDs, which may lead to differences in interpretation if we had used DDDs. Nevertheless, we believe our findings are robust providing guidance to countries seeking to improve the quality and efficiency of their prescribing within finite budgets.
Multiple measures in Scotland in recent years including those affecting the prices of medicines as well as their usage appreciably increased the prescribing of generic (multiple sourced) PPIs versus on-patent PPIs once generic PPIs become available. This led to appreciably reduced expenditure on PPIs in recent years despite utilization increasing over three-fold. There has been some reduction in the prescribing of higher strength PPIs in view of concerns with their long-term safety; however, this needs further investigation before any definitive statements can be made. Overall, we believe these multiple activities in Scotland can be an exemplar for other countries seeking to enhance their prescribing efficiency.
The production of this paper was facilitated by a grant to Alec Morton by the University of Strathclyde under the university’s New Professors’ Fund.
Competing interests: Marion Bennie, Simon Hurding and Sean Macbride Stewart are all employed by NHS Scotland. Alec Morton declares consulting fees from Office of Health Economics and AstraZeneca not related to the current work and not on technologies related to the current work. The authors have no other conflicts of interest to declare.
Provenance and peer review: Not commissioned; externally peer reviewed.
1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
2Division of Clinical Pharmacology, Karolinska, Karolinska Institutet, Stockholm, Sweden
3Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Garankuwa, South Africa
4Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq
5Department of Management Science, Strathclyde Business School, University of Strathclyde, Glasgow, UK
6Pharmacy and Prescribing Support Unit, National Health Service Greater Glasgow and Clyde (NHS GGC), Glasgow, UK
7Therapeutics Branch, Scottish Government, Edinburgh, UK
1. Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, Folgado-de la Rosa DM, Pereira-Exposito A, Gil-Guillen VF. Non-guideline-recommended prescribing of proton pump inhibitors in the general population. Curr Med Res Opin. 2017;33(10):1725-9.
2. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol. 2010;1:141.
3. Woerkom Mv, Piepenbrink H, Godman B, Metz J, Campbell S, Bennie M, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res. 2012;1(6):527-38.
4. NHS Scotland. Polypharmacy indicators [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.therapeutics.scot.nhs.uk/wp-content/uploads/2017/10/Polypharmacy-Indicators.pdf
5. Garuoliené K, Godman B, Gulbinovič J, Schiffers K, Wettermark B. Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):149-52.
6. Hungin AP, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther. 2009;30(4):331-42.
7. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11(51):iii-iv, 1-164.
8. Barkun AN, Adam V, Martel M, Bardou M. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. Value Health. 2013;16(1):14-22.
9. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;(5):CD002095.
10. Whealon SR, Gibbs LM. What is the optimal duration of PPI therapy for healing an ulcer? J Fam Pract. 2015;64(12):805-13.
11. Domingues G, Moraes-Filho JP. Noncompliance is an impact factor in the treatment of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol. 2014;8(7):761-12.
12. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739-54.
13. Mo C, Sun G, Lu ML, Zhang L, Wang YZ, Sun X, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol. 2015;21(17):5382-92.
14. NHS Scotland. National Therapeutic Indicators 2015/2016 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: https://www.sehd.scot.nhs.uk/publications/DC20151126nti_15-16_Full_Document_FINAL.pdf
15. Clinical Knowledge Summaries. NSAIDs – prescribing issues. 2015 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: https://cks.nice.org.uk/nsaids-prescribing-issues#!scenario
16. NHS Scotland. National Therapeutic Indicators 2014/15 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.sehd.scot.nhs.uk/publications/DC20141201nti.pdf
17. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-9.
18. Siau K, Chapman W, Sharma N, Tripathi D, Iqbal T, Bhala N. Management of acute upper gastrointestinal bleeding: an update for the general physician. J R Coll Physicians Edinb. 2017;47:218-30.
19. NHS Greater Glasgow and Clyde. Medicines Update Extra. Oral Proton Pump Inhibitors. 2015 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.ggcprescribing.org.uk/media/uploads/ps_extra/mu_extra_ 04_-_2015.pdf
20. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104 Suppl 2:S27-32.
21. Ramirez E, Lei SH, Borobia AM, Pinana E, Fudio S, Munoz R, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Cur Clin Pharmacol. 2010;5(4):288-97.
22. Ntaios G, Chatzinikolaou A, Kaiafa G, Savopoulos C, Hatzitolios A, Karamitsos D. Evaluation of use of proton pump inhibitors in Greece. Eur J Intern Med. 2009;20(2):171-3.
23. Eid SM, Boueiz A, Paranji S, Mativo C, Landis R, Abougergi MS. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med. 2010;49(23):2561-8.
24. Fraeyman J, Van Hal G, Godman B, Beutels P. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Rev Pharmacoecon Outcomes Res. 2013;13(1):141-51.
25. Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014;5:106.
26. Godman B, Fadare J. Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage. Curr Med Res Opin. 2017;33(11):2085-7.
27. NHS Scotland. National Therapeutic Indicators. 2012 – Baseline data [home-page on the Internet]. [cited 2018 Oct 29]. Available from: http://www.sehd.scot.nhs.uk/pca/PCA2012(M)08report.pdf
28. Freedberg DE, Lamousé-Smith ES, Lightdale JR, Jin Z, Yang Y-X, Abrams JA. Use of acid suppression medication is associated with risk for C. difficile infection in infants and children: a population-based study. Clin Infect Dis. 2015;61(6):912-7.
29. Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. Epidemiol Infect. 2017;145(8):1617-23.
30. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PloS One. 2015;10(6):e0128004.
31. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11-12):1269-81.
32. Jacob L, Hadji P, Kostev K. The use of proton pump inhibitors is positively associated with osteoporosis in postmenopausal women in Germany. Climacteric. 2016;19(5):478-81.
33. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238-46.
34. Danziger J, William JH, Scott DJ, Lee J, Lehman LW, Mark RG, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013;83(4):692-9.
35. Wise J. Gastric acid suppressants are associated with risk of C difficile infection. BMJ. 2017;356:j1584.
36. Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J Gastroenterol. 2017;23(35):6500-15.
37. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740-8.
38. Medicines and Healthcare products Regulatory Agency. Proton pump inhibitors in long-term use: increased risk of fracture [homepage on the Internet]. [cited 2018 Oct 29]. Available from: https://www.gov.uk/drug-safety-update/proton-pump-inhibitors-in-long-term-use-increased-risk-of-fracture
39. Medicines and Healthcare products Regulatory Agency. Proton pump inhibitors in long-term use: reports of hypomagnesaemia [homepage on the Internet]. [cited 2018 Oct 29]. Available from: https://www.gov.uk/drug-safety-update/proton-pump-inhibitors-in-long-term-use-reports-of-hypomagnesaemia
40. NHS Scotland. Scottish Health Protection Network Scottish Guidance No 6, 2017 edition. Guidance on Prevention and Control of Clostridium difficile Infection (CDI) in health and social care settings in Scotland [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.hps.scot.nhs.uk/resourcedocument.aspx?id = 6188
41. NHS Lothian. Lothian Joint Formulary. Proton Pump Inhibitors (PPIs) an information leaflet for patients [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.ljf.scot.nhs.uk/PatientZone/PatientInformationLeaflets/PILs/Proton%20Pump%20Inhibitors%20(PPIs)%20PIL%20v3%20%20 LOT1333.pdf
42. NHS Lothian. Lothian Prescribing Bulletin. April/May 2008 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.ljf.scot.nhs.uk/PrescribingBulletins/2008/lpb/LPB%20Issue%20 No%2035.PDF
43. NHS Lothian. Lothian Prescribing Bulletin. Issue 26. April/May 2007 [home-page on the Internet]. [cited 2018 Oct 29]. Available from: http://www.ljf.scot.nhs.uk/PrescribingBulletins/2007/lpb/LPB%20Issue%20 No%2026.pdf
44. Audit Scotland. Supporting prescribing in general practice – a progress report. June 2003 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.audit-scotland.gov.uk/report/supporting-prescribing-in-general-practice-a-progress-report
45. NHS Scotland. The Scottish Government. National Therapeutic Indicators 2013 – Baseline Report [homepage on the Internet]. [cited 2018 Oct 29]. Available from: https://www.sehd.scot.nhs.uk/publications/DC20131029nti.pdf
46. NHS Scotland. The Scottish Government. National Therapeutic Indicators and Additional Prescribing Measures 2016/2017 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.therapeutics.scot.nhs.uk/wp-content/uploads/2017/07/NTI-16-17-Baseline-Report-Final-Version.pdf
47. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):707-22.
48. Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):469-82.
49. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):125-30.
50. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(1):73-85.
51. NHS Lothian. Lothian Prescribing Bulletin. April/May 2003 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.ljf.scot.nhs.uk/PrescribingBulletins/2003/lpb/LPB%20Issue%20 No%202.pdf
52. Ferner RE, Lenney W, Marriott JF. Controversy over generic substitution. BMJ. 2010;340:c2548.
53. Godman B, Abuelkhair M, Vitry A, Abdu S, Bennie M, Bishop I, et al. Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012;1(2):69-83. doi:10.5639/gabij.2012.0102.017
54. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65-83.
55. Simoens S. A review of generic medicine pricing in Europe. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012;1(1):8-12. doi:10.5639/gabij.2012.0101.004
56. Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br J Clin Pharmacol. 2010;70(3):335-41.
57. Medicines and Healthcare products Regulatory Agency. Antiepileptic drugs: updated advice on switching between different manufacturers’ products. 2017 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: https://www.gov.uk/drug-safety-update/antiepileptic-drugs-updated-advice-on-switching-between-different-manufacturers-products#chm-review-and-update
58. Dunne SS, Shannon B, Cullen W, Dunne CP. Beliefs, perceptions and behaviours of GPs towards generic medicines. Fam Pract. 2014;31(4):467-74.
59. Labiris G, Fanariotis M, Kastanioti C, Alexias G, Protopapas A, Karampitsakos T, et al. Greek physicians’ perceptions on generic drugs in the era of austerity. Scientifica. 2015;2015:251792.
60. NHS Lothian Joint Formulary. 1.3 Antisecretory drugs and mucosal protectants [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.ljf.scot.nhs.uk/LothianJointFormularies/Adult/1.0/1.3/Pages/default.aspx
61. NHS Greater Glasgow and Clyde. Post Script Extra – 6, April 2008. Oral Proton Pump Inhibitors. Data on file.
62. Leporowski A, Godman B, Kurdi A, MacBride-Stewart S, Ryan M, Hurding S, et al. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Rev Pharmacoecon Outcomes Res. 2018;18(6):655-66.
63. ISD Scotland. Community Dispensing. Prescription Cost Analysis [home-page on the Internet]. [cited 2018 Oct 29]. Available from: http://isdscotland.org/Health-Topics/Prescribing-and-Medicines/Community-Dispensing/Prescription-Cost-Analysis/
64. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. ATC/ DDD Index [homepage on the Internet]. [cited 2018 Oct 29]. Available from: https://www.whocc.no/
65. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl Health Econ Health Policy. 2009;7(3):137-47.
66. Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care. 2010;48(9):761-6.
67. Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2009;9(5):475-84.
68. Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11(1):121-9.
69. Pettersson B, Hoffmann M, Wandell P, Levin LA. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy. 2012;104(1):84-91.
70. Zhang F, Wagner AK, Ross-Degnan D. Simulation-based power calculation for designing interrupted time series analyses of health policy interventions. J Clin Epidemiol. 2011;64(11):1252-61.
71. NHS Lothian. Issue 23. October/November 2006 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.ljf.scot.nhs.uk/PrescribingBulletins/2006/lpb/LPB%20Issue%20 No%2023.pdf
72. Audit Scotland. Prescribing in general practice in Scotland. 2013 [homepage on the Internet]. [cited 2018 Oct 29]. Available from: http://www.audit-scotland.gov.uk/docs/health/2013/nr_130124_gp_prescribing.pdf
73. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343:d6333.
74. Marshall S, Fearon P, Dawson J, Quinn TJ. Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2013;13(1):29-42.
75. Slater N, White S, Venables R, Frisher M. Factors associated with polypharmacy in primary care: a cross-sectional analysis of data from The English Longitudinal Study of Ageing (ELSA). BMJ Open. 2018;8(3):e020270.
76. Bennie M, Bishop I, Godman B, Campbell S, Miranda J, Finlayson AE, et al. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland? Qual Prim Care. 2013;21(1):7-15.
77. Bennie M, Bishop I, Godman B, Barbui C, Raschi E, Campbell S, et al. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. Int J Clin Pract. 2013;67(2):170-80.
78. Baumgärtel C, Godman B, Malmström R, Andersen M, Abuelkhair M, Abdu S, et al. What lessons can be learned from the launch of generic clopidogrel? Generics and Biosimilars Initiative Journal (GaBI Journal). 2012;1(2):58-68. doi:10.5639/gabij.2012.0102.016
79. Vončina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):469-79.
80. Barton S. Using clinical evidence. BMJ. 2001;322(7285):503-4.
81. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317(7156):465-8.
82. Fürst J, Čižman M, Mrak J, Kos D, Campbell S, Coenen S, et al. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. Expert Rev Anti Infect Ther. 2015;13(2):279-89.
83. Mares-Garcia E, Palazón-Bru A, Folgado-de la Rosa DM, Pereira-Expósito A, Martinez-Martin Á, Cortés-Castell E, et al. Construction, internal validation and implementation in a mobile application of a scoring system to predict nonadherence to proton pump inhibitors. PeerJ. 2017;5:e3455.
Author for correspondence: Professor Brian Godman, BSc, PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK
Disclosure of Conflict of Interest Statement is available upon request.
Copyright © 2018 Pro Pharma Communications International
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.